


Healthcare News Roundup: Neuro
HSMN NewsFeed - 3 Jan 2014
RegeneRx Receives Orphan Drug Designation for Tβ4 in the Treatment of Neurotrophic Keratopathy
RegeneRx Receives Orphan Drug Designation for Tβ4 in the Treatment of Neurotrophic Keratopathy
HSMN NewsFeed - 31 Dec 2013
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
HSMN NewsFeed - 19 Dec 2013
Nexstim’s Navigated Brain Stimulation Shown to Improve Patient Outcomes in Challenging Brain Surgery
Nexstim’s Navigated Brain Stimulation Shown to Improve Patient Outcomes in Challenging Brain Surgery
HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
HSMN NewsFeed - 16 Dec 2013
Neurotrope, Inc., Appoints James Gottlieb to the Company's Board of Directors
Neurotrope, Inc., Appoints James Gottlieb to the Company's Board of Directors
HSMN NewsFeed - 16 Dec 2013
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
HSMN NewsFeed - 27 Nov 2013
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
